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Objectives This study aimed to evaluate the association of statin exposure and incident diabetes, and subsequent out-
comes in the general population.
Background Cardiovascular events as consequences of atherosclerosis and diabetes are reduced by statins. However, statins
are associated with excessive risk of diabetes occurrence according to clinical trial analyses. From daily-practice
perspectives, it remains unclear whether statin use increases risk; prognoses of diabetes after exposure require
further clarification.
Methods From Taiwan National Health Insurance beneficiaries age 45 years (men) and 55 years (women) before
2004, subjects continuously treated with statins 30 days during 2000 to 2003 and nonusers before 2004
were identified. Among nondiabetic individuals at the cohort entry, controls were matched to statin users on a
4:1 ratio by age, sex, atherosclerotic comorbidities, and year of their entry. Outcomes as diabetes, major ad-
verse cardiovascular events (MACE, the composite of myocardial infarction and ischemic stroke), and in-hospital
deaths were assessed.
Results Over a median of 7.2 years, annual rates of diabetes were significantly higher in statin users (2.4% vs. 2.1%,
p  0.001), whereas MACE (hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0.68 to 0.98 for myocardial
infarction; HR: 0.94; 95% CI: 0.86 to 1.03 for ischemic stroke; HR: 0.91; 95% CI: 0.84 to 0.99 for MACE]) and
in-hospital mortality (HR: 0.61; 95% CI: 0.55 to 0.67]) were less. The risk–benefit analyses suggested that statin
treatment was favorable in high-risk (HR: 0.89; 95% CI: 0.83 to 0.95) and secondary prevention (HR: 0.89; 95%
CI: 0.83 to 0.96) populations. Among diabetic patients, prior statin use was associated with fewer MACE (HR:
0.75; 95% CI: 0.59 to 0.97). In-hospital deaths were similar in statin-related diabetes among high-risk (HR: 1.11;
95% CI: 0.83 to 1.49) and secondary prevention (HR: 1.08; 95% CI: 0.79 to 1.47) subjects compared with nondi-
abetic controls.
Conclusions Risk of diabetes was increased after statins, but outcomes were favorable. (J Am Coll Cardiol 2012;60:
1231–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.019Tackling low-density lipoprotein cholesterol by statin ther-
apy successfully reduces atherosclerotic events in patients at
risk, including individuals with diabetes (1). The latest
analysis from the Cholesterol Treatment Trialists’ Collab-
oration further confirms the efficacy of more intensive
lipid-lowering regimens in the attenuation of cardiovascular
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regard of excessive risk of inci-
dent diabetes soon emerged in
the era of high-potency statins
(6,7). A meta-analysis of 13 clin-
ical trials showed that statin
therapy by a mean of 4 years was
associated with a higher inci-
dence of diabetes (odds ratio:
1.09; 95% CI: 1.02 to 1.17) (8).
Furthermore, the more-intensive
regimens correlated with an in-
crease in risk of diabetes in anal-
yses from selected trials (9,10).
However, the potential mecha-
nisms by which statins influenced
glucose homeostasis are still in
question.
All reported meta-analyses
used tabulated information in-
stead of individual source data. Most trials incorporated into
the meta-analyses enrolled subjects at higher CV risk or
with documented vascular complications. The diagnoses
and adjudications of diabetes, mostly based on reports of
physicians or few occasions of abnormal fasting glucose,
were not standardized (8). Studies involving more intensive
treatment included only certain statins (9,10). The relative
harm and benefit were explored simply in trials enrolling
extremely high-risk patients but not in the general popula-
tion at predominately lower risk. In addition, whether
prognoses differ in subjects complicated with incident dia-
betes after exposure and the benefits of treatment against
the risk of diabetes in clinical practice need to be elucidated
(11). To address those gaps among trials, meta-analyses,
and routine practices, we conducted a retrospective cohort
study by using the Taiwan National Health Insurance Research
Database (NHIRD).
Methods
Data source. The longitudinal data from 1997 to 2009
were obtained from the NHIRD consisting of 1 million
subjects (5% sample of National Health Insurance [NHI]
beneficiaries). Taiwan NHI is a universal, state-operated
health program with the coverage of 98% of the popula-
tion. The NHIRD collects all original NHI claims, which
are updated and maintained regularly by National Health
Research Institutes, and is open to scientific research after
encryption of all personal information.
Study groups. From the NHIRD, individuals without
endocrine disorders and naive to systemic steroid were
selected. Men age 45 years and women age 55 years
during 2000 to 2003 who continuously received statins 30
days during 2000 to 2003 and those naive to statins before
2004 were identified to build the cohort. Those who had
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
CV  cardiovascular
HR  hazard ratio
ICD-9  International
Classification of Diseases-
Ninth Revision
MACE  major adverse
cardiovascular event(s)
MI  myocardial infarction
NHI  National Health
Insurance
NHIRD  National Health
Insurance Research
Databasefollow-up 30 days, who had the presence of International eClassification of Diseases-Ninth Revision (ICD-9) codes of
diabetes or exposure to antidiabetic medications, who had
myocardial infarction (MI), or who received revasculariza-
tion before the entry were excluded. The scheme of enroll-
ing subjects before 2004 and excluding subjects with estab-
lished coronary events was to ensure similar distributions of
background risk between statin users and nonusers because
the National Cholesterol Education Program recommends
more aggressive management in patients at higher risk (12).
omorbidities were confirmed by ICD-9 codes. MI and
schemic stroke were ascertained by ICD-9 codes in the first
osition of the hospital discharge diagnoses. Ischemic stroke
as further validated by the use of brain images or throm-
olysis at the index admission. Hemodialysis was identified
y the procedure claims. The Charlson index was assessed as
he overall severity of comorbidities (13). Healthcare utili-
ation was measured by the annual ambulatory care visits.
rom those naive to statins before 2004, the controls were
atched to statin counterparts on a 4:1 ratio on the basis of
ge, sex, comorbid risk for atherosclerotic events listed in
able 1, and year of their entry into the cohort.
ndpoints and follow-up. Possible diabetes was first iden-
ified as the presence of ICD-9 coding for diabetes in the
HIRD, which has been validated (14,15). The diagnosis was
hen further ascertained by the continuous dispensing of
ntidiabetic medications for 30 days. Major adverse cardio-
ascular events (MACE) were the composite of MI and
schemic stroke. The follow-up started from the cohort entry
o the date of in-hospital death, the last medical claim, or the
rescription of any statin in the controls, whichever came first.
isk– benefit studies. The composite of diabetes and in-
ospital mortality was used for the overall risk–benefit
ssessment across various risk subgroups. Another outcome
ollow-up after diabetes development was created to evalu-
te whether statins before the diagnoses subsequently of-
ered favorable outcomes. The diabetes outcome follow-up
tarted from the date of continuous dispensing of antidia-
etic medications for 30 days to the same definition of
verall follow-up.
tatistical analysis. Baseline characteristics were compared
y Student t test and chi-square test. Kaplan-Meier plots
were generated, and the log-rank test was used to assess the
difference between curves. Cox proportional hazards models
were applied to estimate the crude and adjusted hazard
ratios (HRs) and 95% confidence intervals (CIs). The data
were linked and processed by Microsoft SQL Server 2008
(Microsoft Corporation, Redmond, Washington), and the
statistical analyses were performed with the Statistical Pack-
age for the Social Sciences version 16.0 (SPSS Inc., Chi-
cago, Illinois). A 2-tailed p  0.05 was considered statisti-
ally significant for all analyses.
esults
aseline characteristics. There were 8,412 and 33,648
ligible subjects in the statin and control groups, respec-
1233JACC Vol. 60, No. 14, 2012 Wang et al.
October 2, 2012:1231–8 Statins and the Risk of Diabetestively, for this analysis. The mean age was 63 years, and
approximately 49% of them were women. Most subjects had
hypertension, followed by coronary heart disease (CHD).
There were 6,324 subjects with no risk factor, and 13,601
subjects had hypertension alone. For those who had CHD
as a diagnosis, none of them had prior MI or revasculariza-
tion. In addition, 6% of subjects had been hospitalized for
an ischemic stroke before their entry; a minority had chronic
kidney disease or received hemodialysis. A smaller propor-
tion of the subjects (47%) were qualified for the secondary
prevention, reflecting the nature of the lower-risk cohort of
this study than in meta-analyses. The baseline characteris-
tics were similar with respect to age, sex, and comorbid
atherosclerotic risk as the result of matching (Table 1). The
distributions of other comorbidities and the overall severity
evaluated by the Charlson index were similar, which were
Baseline Characteristics of the SubjectsTable 1 Baseline Characteristics of the Subjects
Variable
Statin
(n  8,412)
Control
(n  33,648) p Value
Age, yrs 63 9 63 9 0.711
Women 4,199 (50) 16,500 (49) 0.149
Comorbid risk for
atherosclerotic events
Hypertension 6,241 (74) 24,824 (74) 0.437
CHD 3,600 (43) 14,623 (44) 0.273
Stroke 555 (7) 2,082 (6) 0.165
CKD 1,083 (13) 4,354 (13) 0.873
Hemodialysis 365 (4) 1,530 (5) 0.411
Low risk* 3,964 (47) 15,961 (47) 0.608
Secondary prevention 3,918 (47) 15,719 (47) 0.818
Other comorbidity
Heart failure 706 (8) 2,923 (9) 0.390
Connective tissue disease 364 (4) 1,347 (4) 0.179
Hemiplegia 240 (3) 960 (3) 1.000
Charlson index 2 1 2 2 0.328
Ambulatory care visit,
no. per year
28 19 27 35 0.789
Statins and doses
Atorvastatin 4,133 (49) NA NA
Daily dose, mg 10 4 NA NA
Fluvastatin 2,542 (30) NA NA
Daily dose, mg 47 20 NA NA
Lovastatin 3,721 (44) NA NA
Daily dose, mg 21 6 NA NA
Pravastatin 2,357 (28) NA NA
Daily dose, mg 12 7 NA NA
Rosuvastatin 1,149 (14) NA NA
Daily dose, mg 8 2 NA NA
Simvastatin 3,833 (46) NA NA
Daily dose, mg 18 6 NA NA
2 statin exposure 5,185 (62) NA NA
Persistence
6 months 5,856 (70) NA NA
3 yrs 2,002 (24) NA NA
Values are mean  SD or n (%). *No risk factor or hypertension only.
CHD  coronary heart disease; CKD  chronic kidney disease; NA  not applicable.concordant with the healthcare utilization indexed by theFigure 1 Kaplan-Meier Curves for Outcomes
Among Statin and Control Groups
(A) Cumulative incidences for newly developed diabetes in the statin and con-
trol groups were 22.7% and 20.8%, respectively. (B) Cumulative incidences for
major adverse cardiovascular (CV) events (the composite of myocardial infarc-
tion [MI] and ischemic stroke) in the statin and control groups were 11.6% and
12.6%, respectively. (C) Cumulative incidences for in-hospital death from all
causes in the statin and control groups were 8.8% and 13.8%, respectively.
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Statins and the Risk of Diabetes October 2, 2012:1231–8annual ambulatory care visits. More than half of statin users
had been exposed to 2 statins (32% had been exposed to
3 statins), and the mean daily doses were relatively small.
The persistence of statins was considerably low.
Endpoints. During the median follow-up of 7.2 years
interquartile range: 6.1 to 8.7 years), there were 5,754 cases
f incident diabetes. Kaplan-Meier curves suggested statin
se increased the hazards of diabetes occurrence (HR: 1.15;
5% CI: 1.08 to 1.22; p  0.001). In addition, there were
69 MI cases, 2,961 new ischemic stroke cases, and 3,484
n-hospital deaths. Statin users had a reduction in risk for
I (HR: 0.82; 95% CI: 0.68 to 0.98; p  0.028) and a
trend for fewer ischemic strokes (HR: 0.94; 95% CI: 0.86 to
1.03; p  0.176), leading to overall fewer MACE (HR:
0.91; 95% CI: 0.84 to 0.99; p  0.031) and in-hospital
deaths (HR: 0.61; 95% CI: 0.55 to 0.67; p  0.001) (Fig. 1).
Subgroup analyses. The susceptibility to diabetes after
statin therapy was similar across age, sex, comorbid risk for
atherosclerotic events, and overall severity of comorbidities.
Statins were significantly associated with an incremental risk
for diabetes regardless of follow-up duration (Fig. 2).
The composite of diabetes and in-hospital mortality exam-
ined whether statin treatment offered preferable prognoses in
subgroups according to overall CV risk. In both low-risk and
primary prevention subgroups, the Kaplan-Meier plots sug-
gested statin users shared similar risk–benefit profiles with
Figure 2 Subgroup Analysis for Incident Diabetes
The risk of incident diabetes in the statin group compared with the control group (
baseline characteristics and the duration of follow-up. The low-risk group included
disease; CKD  chronic kidney disease.controls. Furthermore, compared with the control group, the
benefit of statin use in preventing in-hospital fatalities out-
weighed the risk of developing diabetes in the high-risk
subgroup (HR: 0.89; 95% CI: 0.83 to 0.95; p 0.001) and in
secondary prevention subjects (HR: 0.89; 95% CI: 0.83 to
0.96; p  0.002) (Fig. 3).
Outcomes after developing diabetes. The cohort was
recategorized according to the presence of diabetes and prior
statin therapy. To evaluate the subsequent prognoses of
diabetic subjects after exposure, 4 groups were created
comprising nondiabetic controls (n  29,332), diabetic
controls (n  4,316), diabetic patients with prior statin use
(n  1,387), and nondiabetic patients with prior statin use
(n  7,025). Among these 4 groups, the incidences of
MACE were 12, 21, 16, and 12 per 1,000 person-years,
respectively, and the annual in-hospital mortality rates were
1.4%, 2.0%, 1.6%, and 0.8%, respectively. Kaplan-Meier
curves suggested that subjects who received statins without
developing diabetes had significantly better outcomes, and
those developing diabetes without prior statin use were at an
increase in hazards of MACE and in-hospital death. Sub-
jects treated with statins followed by diabetes occurrence
had an increase in risk of MACE (HR: 1.30; 95% CI: 1.03
to 1.64; p  0.025) and in-hospital death (HR: 1.38; 95%
I: 1.10 to 1.73; p  0.005) compared with nondiabetic
controls. Among diabetic patients, prior statin therapy pro-
ted by hazard ratios and 95% confidence intervals) is shown, stratified by the
ts with no atherosclerotic risk factor or hypertension only. CHD  coronary heartpresen
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October 2, 2012:1231–8 Statins and the Risk of Diabetesvided an advantage in the reduction of MACE (HR: 0.75;
95% CI: 0.59 to 0.97; p  0.027) and a trend for less
n-hospital mortality (HR: 0.82; 95% CI: 0.64 to 1.04; p 
.105) (Fig. 4). After accounting for background risk,
ncident diabetes after statin therapy was associated with an
ncreased risk for in-hospital death overall but not in the
igh-risk and secondary prevention cohorts compared with
he nondiabetic controls (Table 2).
iscussion
n this longitudinal cohort study, we found that statin
xposure was associated with excessive risk of incident
iabetes. The risk–benefit analyses favored statin use in the
igh-risk and secondary prevention subjects. Another prin-
Figure 3 Risk–Benefit Analysis Stratified by Baseline Risk and
The endpoint for risk–benefit assessment was the first occurrence of incident diab
the statin and control groups among low-risk subjects (hazard ratio [HR]: 0.98; 95
favored statin treatment in the high-risk subjects (HR: 0.89; 95% CI: 0.83 to 0.95
among subjects indicated for primary prevention (HR: 0.97; 95% CI: 0.90 to 1.04;
for secondary prevention (HR: 0.89; 95% CI: 0.83 to 0.96; p  0.002).ipal result is that subjects developing diabetes after statin rherapy had higher rates of MACE and in-hospital death,
ut the hazard was insignificant in the high-risk and
econdary prevention subjects.
Unlike in the WOSCOP study, suggesting a 30% risk
eduction by pravastatin in men age 65 years (5), our
esults from the clinical-practice perspective were in line
ith the findings from the meta-analysis of clinical trials
howing that statins were associated with an increased risk
f newly developed diabetes (8). The absolute risk increase
y statins was comparably small in both studies (0.3% in our
tudy; 0.4% in the meta-analysis). However, most trials
argeted specific CV outcomes but not primarily diabetes
ccurrence. Methods for diagnosing diabetes were not
niform across trials, and some adopted only physician-
ations for Statins
r in-hospital death from all causes. (A) The risk–benefit profile was similar in
fidence interval [CI]: 0.91 to 1.06; p  0.587). (B) The risk–benefit profile
0.001). (C) The risk–benefit profile was similar in the statin and control groups
.372). (D) The risk–benefit profile favored statin treatment in subjects indicatedIndic
etes o
% con
; p 
p  0eporting cases or results from few occasions of fasting
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Statins and the Risk of Diabetes October 2, 2012:1231–8glucose. This might not reflect the true consequences in the
real-world exposure of statins. Our study combined the
clinical diagnoses and the confirmation from pharmacy
claims. The hazard of developing diabetes was consistent
across age, sex, and comorbidities. Furthermore, we ex-
plored the benefits of statin therapy in clinical practice. In
general, treatment of statins prevented 1 fatal event in 202
subjects and led to 1 case of diabetes in 301 patients per
year. However, the information should be reviewed with
Figure 4 Kaplan-Meier Survival Curves for Subjects Categorized
by the Presence of Diabetes and Statin Use
(A) Estimated rates of major CV event were 11.5% for nondiabetic individuals
without prior statin use, 17.0% for diabetic patients without prior statin use,
12.5% for diabetic patients with prior statin use, and 11.0% for nondiabetic
individuals with prior statin use. (B) Estimated rates of in-hospital death from
all causes were 14.1% for nondiabetic individuals without prior statin use,
20.3% for diabetic patients without prior statin use, 15.0% for diabetic patients
with prior statin use, and 8.7% for nondiabetic individuals with prior statin use.
DM  diabetes mellitus.caution because the incidence of diabetes in our study was21 per 1,000 person-years, which was relatively more than
in other investigations (16,17). Ethnic differences in diabe-
tes occurrence and susceptibility to statins were reported
(17–19). Therefore, we may have overestimated the poten-
tial risk for diabetes against the benefits of statins, especially
in the cohort with a lower diabetes incidence.
Statins carrying an increased risk for diabetes were also
reported in postmenopausal women from the analyses of the
Women’s Health Initiative (19). All statins of varying
potency correlated with hazards for diabetes. The women in
our study shared a risk for diabetes that was similar to that
for men after exposure to statins. Even though we enrolled
women age 55 years, we could not identify whether they
were menopausal or took hormone replacement therapy. In
addition, a dose-dependent increment in the risk of incident
diabetes after statin use was further suggested by the
meta-analysis of 5 trials focusing on subjects at extremely
high CV risk (10). For a mean follow-up of 4.9 years,
intensive-dose regimens increased the risk of diabetes by
12% but reduced MACE by 16% compared with moderate
doses. Our study did not explore the dose-dependent effect
of statins because 62% of users had been exposed to 2
tatins, as is common in clinical practice. On comparison of
hose who received only a single statin, the dose-dependent
azard was not found (HR: 1.01; 95% CI: 0.83 to 1.22; p
.938, low vs. high daily dose). Most physicians prescribed
tatins at medium or lower equipotency doses in routine
ractice (20), unlike in clinical trials. The long-term adher-
nce was suboptimal even in high-risk subjects (21).
hether persistent high-dose statins have greater hazards
han usual doses of statins among populations with lower
V risk requires further investigation.
There were 44% of subjects in the control group who had
HD as a diagnosis. Previous reports of disparities between
linical practices and trials suggested elderly persons,
omen, and comorbidities were negatively associated with
tatin use (22,23). In our subjects with CHD, the distribu-
ions of age and sex were similar, but the Charlson index
as higher among controls (1.8  1.6 vs. 2.0  1.7, p 
0.001). After adjusting for the Charlson index, statins signif-
icantly attributed to the risk of diabetes (HR: 1.13; 95% CI:
1.03 to 1.24; p 0.007) and the reduction of in-hospital death
(HR: 0.64; 95% CI: 0.56 to 0.72; p  0.001).
The mechanisms responsible for the increased risk of
diabetes after statins were not the scope of our design. The
pathway of interfering isoprenoids by statins leading to the
attenuation of glucose transporter 4 expression was pro-
posed (24,25). The evidence from the patient care database
supported the cellular and animal findings that statin treatment
significantly increased fasting plasma glucose in both nondia-
betic and diabetic patients (26). However, there was still
controversy over laboratory versus clinical results, especially
whether it was the common off-target effects across all statins
(27–29). Our results from 3,227 subjects who received a single
statin were in agreement with the meta-analyses that incorpo-
rated most available statins, suggesting statins as the class with
stroke,
1237JACC Vol. 60, No. 14, 2012 Wang et al.
October 2, 2012:1231–8 Statins and the Risk of Diabeteslittle heterogeneity for an increased risk for diabetes (8,10).
Other than rosuvastatin and fluvastatin (HR: 1.26; 95% CI:
1.00 to 1.59; p 0.052), atorvastatin (HR: 1.58; 95% CI: 1.34
to 1.86; p  0.001), lovastatin (HR: 1.77; 95% CI: 1.57 to
2.00; p 0.001), pravastatin (HR: 1.69; 95% CI: 1.35 to 2.12;
p 0.001), and simvastatin (HR: 1.57; 95% CI: 1.31 to 1.86;
p  0.001) were hazards for diabetes compared with the
control group.
The identification of factors attributing to new-onset
diabetes after statin exposure may help physicians identify
subjects who are susceptible to diabetes occurrence. Inde-
pendent predictors such as age, baseline fasting glucose and
triglycerides, body mass index, and hypertension were ex-
plored (5,8,9). Some of those variables were highly related
to the consequences of endothelial dysfunction and insulin
resistance, the precursors or markers of diabetes (30).
Therefore, surveillance for abnormal glucose homeostasis
should be persistent in all subjects taking statins.
Study strengths and limitations. With the use of the
nationwide cohort database, the strengths of our design
include the following: We provided a longer follow-up than
clinical trials and helped to evaluate the long-term risk and
benefit. The endpoints ascertained under the rigorous def-
initions may be a useful reference for clinicians. Our study
was the first to investigate the risk and benefit of statins in
the general population, and the robust results warrant the
cautious evaluation of statin use in the low-risk population
since the encouragement of primary prevention in the
low-cost statin era (31). However, the findings and impli-
cations of our study should be interpreted within the context
of several weaknesses. The investigation was retrospective,
and subjects with established coronary events, who were
mostly likely to benefit from statins, were excluded. The
analyses may overlook the potentially favorable prognoses of
diabetes with prior statin therapy in the secondary preven-
tion cohort. The conclusions may not be generally applica-
ble to other populations. However, our results were consis-
Univariate and Multivariate Analyses of In-Hospital DeathsAccording to Status of Diabetes and Prior Exposure of StatinsTable 2 Univariate and Multivariate Analyses of In-Ho pital DeaAccording to Status of Diabetes and Prior Exposure of
Nondiabetic Individuals
Without Prior Statin Use
Dia
Withou
Overall cohort
N 29,332
Crude Reference 1.7
Adjusted* Reference 1.9
High-risk cohort†
N 15,481
Crude Reference 1.4
Adjusted* Reference 1.6
Secondary prevention cohort
N 13,733
Crude Reference 1.4
Adjusted* Reference 1.6
Values are hazard ratios (95% confidence intervals). *Adjusted for age, sex, hypertension, CHD,
hypertension.tent with the findings of published analyses acrossethnicities and various CV risk groups. The mean daily dose
was relatively lower than doses in clinical trials, and the
dose-dependent relation between statins and diabetes could
not be confirmed in our study. There was no individual
information, such as family history of diabetes, tobacco use,
and exact compliance to drugs, and no laboratory result was
available in the claims database. Therefore, we could not
extrapolate the association between incident diabetes and
low-density lipoprotein cholesterol reduction and other
metabolic profiles as found by other investigators. We used
in-hospital all-cause mortality in this analysis because the
encrypted NHIRD could not be linked to the national death
registry to precisely capture all deaths. According to the
health statistics of Taiwan, 20% of fatalities were due to CV
diseases and in-hospital deaths accounted for 42% of overall
mortality. Therefore, out-of-hospital deaths may bias our
results. However, we explored the potential impacts of the
unrecognized deaths with 2 sets of analyses by linking our
data to the withdrawal certificate records; statin treatment
showed superiority in all-cause mortality scenarios and
noninferiority in the worst-case scenarios (Online Figs. 1
and 2). Finally, we enrolled subjects who received statins
before 2004, when rosuvastatin and pitavastatin were not
available. The odds ratio for developing diabetes was 1.18
(95% CI: 1.04 to 1.33) for rosuvastatin compared with the
placebo in the pooled analysis (8). The reported phase III
and IV studies that compared pitavastatin with statins had
small sample sizes and short follow-ups (2 years) (32).
The impact of pitavastatin on glucose metabolism requires
further observation.
Conclusions
Statin use is associated with an increase in diabetes occur-
rence. However, the benefit of statin treatment overweighs
the hazard in high-risk subjects and secondary prevention
subjects. The outcomes of those who developed diabetes
ins
atients
Statin Use
Diabetic Patients
With Prior Statin Use
Nondiabetic Individuals
With Prior Statin Use
6 1,387 7,025
1–1.91) 1.38 (1.10–1.73) 0.59 (0.54–0.66)
0–2.15) 1.54 (1.23–1.92) 0.58 (0.53–0.64)
6 728 3,720
5–1.69) 1.11 (0.83–1.49) 0.61 (0.54–0.68)
5–1.96) 1.31 (0.98–1.75) 0.62 (0.55–0.70)
6 652 3,266
2–1.67) 1.08 (0.79–1.47) 0.61 (0.53–0.69)
4–1.98) 1.28 (0.94–1.73) 0.62 (0.55–0.71)
chronic kidney disease, hemodialysis, and Charlson index. †One or more risk factor other thanths
Stat
betic P
t Prior
4,31
0 (1.5
1 (1.7
2,20
5 (1.2
9 (1.4
1,98
3 (1.2
8 (1.4after statin use are generally favorable in those subgroups.
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should be incorporated into the care program to optimize
overall risk management.
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